福安药业
(300194)
| 流通市值：40.75亿 | | | 总市值：50.09亿 |
| 流通股本：9.68亿 | | | 总股本：11.90亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 467,678,211.11 | 2,391,468,105.37 | 1,995,281,936.35 | 1,433,012,335.07 |
| 营业收入 | 467,678,211.11 | 2,391,468,105.37 | 1,995,281,936.35 | 1,433,012,335.07 |
| 二、营业总成本 | 424,656,082.74 | 2,124,236,673.71 | 1,733,508,475.64 | 1,249,446,737.69 |
| 营业成本 | 277,152,681 | 1,124,997,486.04 | 938,496,920.59 | 668,254,706.15 |
| 税金及附加 | 6,468,368 | 30,752,914.2 | 23,427,541.74 | 16,142,370.85 |
| 销售费用 | 58,120,765.7 | 563,426,225.62 | 492,031,678.93 | 378,139,951.69 |
| 管理费用 | 53,478,613.35 | 258,776,299.62 | 189,140,117.54 | 125,639,991.4 |
| 研发费用 | 30,330,798.21 | 153,223,657.68 | 95,368,357.23 | 64,296,645.51 |
| 财务费用 | -895,143.52 | -6,939,909.45 | -4,956,140.39 | -3,026,927.91 |
| 其中:利息费用 | 1,919,204.41 | 23,338,101.62 | 18,092,076.42 | 12,520,497.13 |
| 其中:利息收入 | 6,155,799.35 | 29,808,752.85 | 23,170,390.49 | 15,372,940.2 |
| 加:公允价值变动收益 | 60,712.33 | -32,735,646.45 | 13,465.75 | 0 |
| 加:投资收益 | 30,950,153.11 | 76,987,951.6 | 54,150,158.46 | 42,244,671.48 |
| 资产处置收益 | 0 | 9,036.8 | 231,063.13 | 142,005.09 |
| 资产减值损失(新) | -3,192,658.29 | -34,741,850.61 | -11,796,662.05 | -6,536,449.5 |
| 信用减值损失(新) | -3,842,431.67 | -3,792,040.34 | 4,992,614.01 | 2,196,077.75 |
| 其他收益 | 6,157,771.01 | 47,887,951.1 | 37,850,621.28 | 28,317,474.66 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 73,155,674.86 | 320,846,833.76 | 347,214,721.29 | 249,929,376.86 |
| 加:营业外收入 | 132,705.57 | 4,697,109.41 | 1,723,006.51 | 1,370,679.51 |
| 减:营业外支出 | 800,760.47 | 13,347,389.08 | 6,231,263.62 | 5,456,984.66 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 72,487,619.96 | 312,196,554.09 | 342,706,464.18 | 245,843,071.71 |
| 减:所得税费用 | 3,689,880.99 | 34,025,539.11 | 40,787,400.46 | 30,291,098.76 |
| 六、净利润 | 68,797,738.97 | 278,171,014.98 | 301,919,063.72 | 215,551,972.95 |
| 持续经营净利润 | 68,797,738.97 | 278,171,014.98 | 301,919,063.72 | 215,551,972.95 |
| 归属于母公司股东的净利润 | 69,049,030.79 | 279,837,280.89 | 301,606,802.14 | 216,477,522.42 |
| 少数股东损益 | -251,291.82 | -1,666,265.91 | 312,261.58 | -925,549.47 |
| (一)基本每股收益 | 0.06 | 0.24 | 0.25 | 0.18 |
| (二)稀释每股收益 | 0.06 | 0.24 | 0.25 | 0.18 |
| 八、其他综合收益 | -21,233,854.46 | 30,781,583.67 | 11,273,867.2 | 15,625,329.85 |
| 归属于母公司股东的其他综合收益 | -21,233,854.46 | 30,781,583.67 | 11,273,867.2 | 15,625,329.85 |
| 九、综合收益总额 | 47,563,884.51 | 308,952,598.65 | 313,192,930.92 | 231,177,302.8 |
| 归属于母公司股东的综合收益总额 | 47,815,176.33 | 310,618,864.56 | 312,880,669.34 | 232,102,852.27 |
| 归属于少数股东的综合收益总额 | -251,291.82 | -1,666,265.91 | 312,261.58 | -925,549.47 |
| 公告日期 | 2025-04-24 | 2025-04-24 | 2024-10-25 | 2024-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |